KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Net Income (2016 - 2025)

Historic Net Income for Dynavax Technologies (DVAX) over the last 17 years, with Q3 2025 value amounting to $26.9 million.

  • Dynavax Technologies' Net Income rose 5304.65% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year decrease of 31157.45%. This contributed to the annual value of $27.3 million for FY2024, which is 52743.78% up from last year.
  • Latest data reveals that Dynavax Technologies reported Net Income of $26.9 million as of Q3 2025, which was up 5304.65% from $18.7 million recorded in Q2 2025.
  • Dynavax Technologies' 5-year Net Income high stood at $128.8 million for Q2 2022, and its period low was -$96.1 million during Q1 2025.
  • Moreover, its 5-year median value for Net Income was $14.3 million (2023), whereas its average is $19.1 million.
  • Per our database at Business Quant, Dynavax Technologies' Net Income skyrocketed by 311917.81% in 2024 and then tumbled by 100469.13% in 2025.
  • Quarter analysis of 5 years shows Dynavax Technologies' Net Income stood at $99.8 million in 2021, then plummeted by 32.12% to $67.7 million in 2022, then plummeted by 99.68% to $219000.0 in 2023, then surged by 3119.18% to $7.0 million in 2024, then surged by 281.94% to $26.9 million in 2025.
  • Its Net Income was $26.9 million in Q3 2025, compared to $18.7 million in Q2 2025 and -$96.1 million in Q1 2025.